Psychemedics Corporation (PMD) News
Filter PMD News Items
PMD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PMD News From Around the Web
Below are the latest news stories about PSYCHEMEDICS CORP that investors may wish to consider to help them evaluate PMD as an investment opportunity.
Psychemedics Corporation Appoints Daniella Mehalik as VP - FinanceACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she wil |
Psychemedics Corporation Reports Third Quarter 2023 Financial ResultsACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company’s revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net lo |
Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug ScreenPsychemedics’ FDA-cleared alternative 5-panel drug screen replaces marijuana with fentanyl.ACTON, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to the paramount threat |
Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue OfficerACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record of leadership and a strong background in revenue growth and optimization, Shoemaker brings a wealth of experience to h |
Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)ACTON, Mass., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger, upon his entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Hullinger received an inducement grant option to purchase up to 300,000 shares of common stock. The inducement awards wer |
Psychemedics Corporation Reports Second Quarter 2023 Financial ResultsACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company’s revenue for the quarter ended June 30, 2023, was $5.5 million versus $6.5 million for the quarter ended June 30, 2022, a decrease of 15%. Net loss for the quarter ended June 30, 2023, was $(726,000) or $(0.13) per diluted share, versus net loss of $(338,0 |
Psychemedics Corporation Announces CEO Succession PlanBrian Hullinger Will Succeed Ray Kubacki as CEO Effective August 17, 2023 Mr. Hullinger Brings 30 Years of Leadership Experience and a Proven Track Record of Driving Growth ACTON, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced today that its board of directors has approved a transition plan for the Company’s President and CEO position. Effective August 17th, current Chairman of the Board, |
Do These 3 Checks Before Buying Psychemedics Corporation (NASDAQ:PMD) For Its Upcoming DividendIt looks like Psychemedics Corporation ( NASDAQ:PMD ) is about to go ex-dividend in the next four days. The ex-dividend... |
Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07Psychemedics Corporation's ( NASDAQ:PMD ) investors are due to receive a payment of $0.07 per share on 8th of June. The... |
Psychemedics Corporation Reports First Quarter 2023 Financial Results and Declares Cash DividendACTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2023, and the declaration of a cash dividend of $0.07 per share to be paid on June 8, 2023, to shareholders of record as of May 25, 2023. The Company’s revenue for the quarter ended March 31, 2023, was $5.9 million versus $6.5 million for the quarter ended March 31, 2022, a d |